Ab&B Bio-Tech Co., Ltd. (JS) is a China-based biotechnology company dedicated to the research, development, manufacturing, and commercialization of innovative human vaccines. It focuses on a diverse product pipeline that includes core offerings such as the quadrivalent subunit influenza vaccine, which targets four influenza virus strains and is commercially available for ages three and above, and the lyophilized human rabies vaccine candidate, alongside 11 other candidates encompassing viral vaccines, bacterial vaccines, conjugate vaccines, recombinant subunit vaccines, and mRNA vaccines. The company maintains R&D centers in Shanghai and Taizhou with pilot platforms to advance these projects, while its GMP-compliant production facilities support full-cycle development from innovation to market delivery. Primarily serving the domestic market, Ab&B Bio-Tech Co., Ltd. (JS) plays a vital role in enhancing public health through advanced vaccine technologies that meet international standards. Founded in 2015 and headquartered in Taizhou, Jiangsu Province, it operates specialized production parks equipped for influenza vaccine lines and expanded capabilities for broader pipeline industrialization.